NRIX   $25.05  1.21% Market Closed After Close 25.06 0.04%

Nurix Therapeutics Inc
Last Events:

2023-08-09 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it crossed the signal line from the top and falls. These factors mean that the market confirms the tendency to fall. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Signal in MACD changed from bearish recovery to bullish reversal. Oscillator MACD is in the negative territory it crossed the signal line from the bottom and grows. These factors mean that the market confirms the end of the downward trend. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-04 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: signal line crossed the middle level.

2023-08-03 Trend pattern changed from канал to нисходящий треугольник.

2023-08-03 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-03 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.


Current temperature: 3.40
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 12
Target Price Mean 29.00
Mean unverified/preliminary 29.00 / 29.00
Target Price Low / High 15.00 / 36.00
Median / STD DEV 30.00 / 5.41
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Buy Sell
rsi ActivelyBuy ActivelyBuy Sell
macd Sell None None
stoch None None None
ma20 Sell Buy None
ma50 None None None
ma100 None Buy None
Candlestick PatternSept. 18, 2024 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US67080M1036
ceo Dr. Arthur T. Sands M.D., Ph.D.
Website https://www.nurixtx.com
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.